keyword
MENU ▼
Read by QxMD icon Read
search

Lassa fever

keyword
https://www.readbyqxmd.com/read/29295909/lamp1-increases-the-efficiency-of-lassa-virus-infection-by-promoting-fusion-in-less-acidic-endosomal-compartments
#1
Christine E Hulseberg, Lucie Fénéant, Katarzyna M Szymańska, Judith M White
Lassa virus (LASV) is an arenavirus whose entry into host cells is mediated by a glycoprotein complex (GPC) comprised of a receptor binding subunit, GP1, a fusogenic transmembrane subunit, GP2, and a stable signal peptide. After receptor-mediated internalization, arenaviruses converge in the endocytic pathway, where they are thought to undergo low-pH-triggered, GPC-mediated fusion with a late endosome membrane. A unique feature of LASV entry is a pH-dependent switch from a primary cell surface receptor (α-dystroglycan) to an endosomal receptor, lysosomal-associated membrane protein (Lamp1)...
January 2, 2018: MBio
https://www.readbyqxmd.com/read/29287681/alphavirus-vector-based-replicon-particles-expressing-multivalent-cross-protective-lassa-virus-glycoproteins
#2
Min Wang, Jenny Jokinen, Irina Tretyakova, Peter Pushko, Igor S Lukashevich
Lassa virus (LASV) is the most prevalent rodent-borne arenavirus circulated in West Africa. With population at risk from Senegal to Nigeria, LASV causes Lassa fever and is responsible for thousands of deaths annually. High genetic diversity of LASV is one of the challenges for vaccine R&D. We developed multivalent virus-like particle vectors (VLPVs) derived from the human Venezuelan equine encephalitis TC-83 IND vaccine (VEEV) as the next generation of alphavirus-based bicistronic RNA replicon particles. The genes encoding VEEV structural proteins were replaced with LASV glycoproteins (GPC) from distantly related clades I and IV with individual 26S promoters...
December 26, 2017: Vaccine
https://www.readbyqxmd.com/read/29238121/epidemic-preparedness-and-management-a-guide-on-lassa-fever-outbreak-preparedness-plan
#3
REVIEW
Akinola Ayoola Fatiregun, Elvis Efe Isere
Epidemic prone diseases threaten public health security. These include diseases such as cholera, meningitis, and hemorrhagic fevers, especially Lassa fever for which Nigeria reports considerable morbidity and mortality annually. Interestingly, where emergency epidemic preparedness plans are in place, timely detection of outbreaks is followed by a prompt and appropriate response. Furthermore, due to the nature of spread of Lassa fever in an outbreak setting, there is the need for health-care workers to be familiar with the emerging epidemic management framework that has worked in other settings for effective preparedness and response...
January 2017: Nigerian Medical Journal: Journal of the Nigeria Medical Association
https://www.readbyqxmd.com/read/29186289/discharge-criteria-for-patient-with-lassa-fever-infection
#4
Emanuele Nicastri, Francesco Vairo, Giuseppe Ippolito
No abstract text is available yet for this article.
November 24, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29155659/us-federal-travel-restrictions-for-persons-with-higher-risk-exposures-to-communicable-diseases-of-public-health-concern
#5
Laura A Vonnahme, M Robynne Jungerman, Reena K Gulati, Petra Illig, Francisco Alvarado-Ramy
Published guidance recommends controlled movement for persons with higher-risk exposures (HREs) to communicable diseases of public health concern; US federal public health travel restrictions (PHTRs) might be implemented to enforce these measures. We describe persons eligible for and placed on PHTRs because of HREs during 2014-2016. There were 160 persons placed on PHTRs: 142 (89%) involved exposure to Ebola virus, 16 (10%) to Lassa fever virus, and 2 (1%) to Middle East respiratory syndrome coronavirus. Most (90%) HREs were related to an epidemic...
December 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/29138016/the-challenges-of-detecting-and-responding-to-a-lassa-fever-outbreak-in-an-ebola-affected-setting
#6
E L Hamblion, P Raftery, A Wendland, E Dweh, G S Williams, R N C George, L Soro, V Katawera, P Clement, A N Gasasira, E Musa, T K Nagbe
OBJECTIVES: Lassa fever (LF), a priority emerging pathogen likely to cause major epidemics, is endemic in much of West Africa and is difficult to distinguish from other viral hemorrhagic fevers, including Ebola virus disease (EVD). Definitive diagnosis requires laboratory confirmation, which is not widely available in affected settings. The public health action to contain a LF outbreak and the challenges encountered in an EVD-affected setting are reported herein. METHODS: In February 2016, a rapid response team was deployed in Liberia in response to a cluster of LF cases...
January 2018: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/29135337/dna-vaccines-elicit-durable-protective-immunity-against-individual-or-simultaneous-infections-with-lassa-and-ebola-viruses-in-guinea-pigs
#7
Kathleen A Cashman, Eric R Wilkinson, Suzanne E Wollen, Joshua D Shamblin, Justine M Zelko, Jeremy J Bearss, Xiankun Zeng, Kate E Broderick, Connie S Schmaljohn
We previously developed optimized DNA vaccines against both Lassa fever and Ebola hemorrhagic fever viruses and demonstrated that they were protective individually in guinea pig and nonhuman primate models. In this study, we vaccinated groups of strain 13 guinea pigs two times, four weeks apart with 50 µg of each DNA vaccine or a mock vaccine at discrete sites by intradermal electroporation. Five weeks following the second vaccinations, guinea pigs were exposed to lethal doses of Lassa virus, Ebola virus, or a combination of both viruses simultaneously...
November 14, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29083948/chimpanzee-adenoviral-vectors-as-vaccines-for-outbreak-pathogens
#8
Katie Ewer, Sarah Sebastian, Alexandra J Spencer, Sarah Gilbert, Adrian V S Hill, Teresa Lambe
The 2014-15 Ebola outbreak in West Africa highlighted the potential for large disease outbreaks caused by emerging pathogens and has generated considerable focus on preparedness for future epidemics. Here we discuss drivers, strategies and practical considerations for developing vaccines against outbreak pathogens. Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specific cellular and humoral immunity in all age groups, as well as circumventing the problem of pre-existing immunity encountered with human Ad vectors...
October 30, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29070682/epistastic-interactions-within-the-jun%C3%A3-n-virus-envelope-glycoprotein-complex-provide-an-evolutionary-barrier-to-reversion-in-the-live-attenuated-candid-1-vaccine
#9
Joanne York, Jack H Nunberg
The Candid#1 strain of Junín virus was developed using a conventional attenuation strategy of serial passage in non-host animals and cultured cells. The live-attenuated Candid#1 vaccine is used in Argentina to protect at-risk individuals against Argentine hemorrhagic fever, but has not been licensed in the United States. Recent studies have revealed that Candid#1 attenuation is entirely dependent on a phenylalanine-to-isoleucine substitution at position 427 in the fusion subunit (GP2) of the viral envelope glycoprotein complex (GPC), thereby raising concerns regarding the potential for reversion to virulence...
October 25, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29045192/a-dna-vaccine-delivered-by-dermal-electroporation-fully-protects-cynomolgus-macaques-against-lassa-fever
#10
Kathleen A Cashman, Eric R Wilkinson, Carl I Shaia, Paul R Facemire, Todd M Bell, Jeremy J Bearss, Joshua D Shamblin, Suzanne E Wollen, Kate E Broderick, Niranjan Y Sardesai, Connie S Schmaljohn
Lassa virus (LASV) is an ambisense RNA virus in the Arenaviridae family and is the etiological agent of Lassa fever, a severe hemorrhagic disease endemic to West and Central Africa. (1,2) There are no US Food and Drug Administration (FDA)-licensed vaccines available to prevent Lassa fever. (1,2) in our previous studies, we developed a gene-optimized DNA vaccine that encodes the glycoprotein precursor gene of LASV (Josiah strain) and demonstrated that 3 vaccinations accompanied by dermal electroporation protected guinea pigs from LASV-associated illness and death...
October 18, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29031848/local-national-and-regional-viral-haemorrhagic-fever-pandemic-potential-in-africa-a-multistage-analysis
#11
David M Pigott, Aniruddha Deshpande, Ian Letourneau, Chloe Morozoff, Robert C Reiner, Moritz U G Kraemer, Shannon E Brent, Isaac I Bogoch, Kamran Khan, Molly H Biehl, Roy Burstein, Lucas Earl, Nancy Fullman, Jane P Messina, Adrian Q N Mylne, Catherine L Moyes, Freya M Shearer, Samir Bhatt, Oliver J Brady, Peter W Gething, Daniel J Weiss, Andrew J Tatem, Luke Caley, Tom De Groeve, Luca Vernaccini, Nick Golding, Peter Horby, Jens H Kuhn, Sandra J Laney, Edmond Ng, Peter Piot, Osman Sankoh, Christopher J L Murray, Simon I Hay
BACKGROUND: Predicting when and where pathogens will emerge is difficult, yet, as shown by the recent Ebola and Zika epidemics, effective and timely responses are key. It is therefore crucial to transition from reactive to proactive responses for these pathogens. To better identify priorities for outbreak mitigation and prevention, we developed a cohesive framework combining disparate methods and data sources, and assessed subnational pandemic potential for four viral haemorrhagic fevers in Africa, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, and Marburg virus disease...
December 16, 2017: Lancet
https://www.readbyqxmd.com/read/29019310/lessons-learnt-from-imported-cases-and-onward-transmission-of-lassa-fever-in-europe-support-broader-management-of-viral-haemorrhagic-fevers
#12
Roger Hewson
No abstract text is available yet for this article.
September 2017: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
https://www.readbyqxmd.com/read/29019309/management-of-a-lassa-fever-outbreak-rhineland-palatinate-germany-2016
#13
Lutz Ehlkes, Maja George, Gerhard Samosny, Florian Burckhardt, Manfred Vogt, Stefan Bent, Klaus Jahn, Philipp Zanger
Due to rapid diagnosis and isolation of imported cases, community outbreaks of viral haemorrhagic fevers (VHF) are considered unlikely in industrialised countries. In March 2016, the first documented locally acquired case of Lassa fever (LF) outside Africa occurred, demonstrating the disease's potential as a cross-border health threat. We describe the management surrounding this case of LF in Rhineland-Palatinate - the German federal state where secondary transmission occurred. Twelve days after having been exposed to the corpse of a LF case imported from Togo, a symptomatic undertaker tested positive for Lassa virus RNA...
September 2017: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
https://www.readbyqxmd.com/read/29019307/control-measures-following-a-case-of-imported-lassa-fever-from-togo-north-rhine-westphalia-germany-2016
#14
Clara Lehmann, Matthias Kochanek, Diana Abdulla, Stephan Becker, Boris Böll, Anne Bunte, Daniel Cadar, Arno Dormann, Markus Eickmann, Petra Emmerich, Torsten Feldt, Christina Frank, Jochen Fries, Martin Gabriel, Udo Goetsch, René Gottschalk, Stephan Günther, Michael Hallek, Dieter Häussinger, Christian Herzog, Björn Jensen, Felix Kolibay, Michael Krakau, Georg Langebartels, Toni Rieger, Lars Schaade, Jonas Schmidt-Chanasit, Edgar Schömig, Gundolf Schüttfort, Alexander Shimabukuro-Vornhagen, Michael von Bergwelt-Baildon, Ulrike Wieland, Gerhard Wiesmüller, Timo Wolf, Gerd Fätkenheuer
In a patient transferred from Togo to Cologne, Germany, Lassa fever was diagnosed 12 days post mortem. Sixty-two contacts in Cologne were categorised according to the level of exposure, and gradual infection control measures were applied. No clinical signs of Lassa virus infection or Lassa specific antibodies were observed in the 62 contacts. Thirty-three individuals had direct contact to blood, other body fluids or tissue of the patients. Notably, with standard precautions, no transmission occurred between the index patient and healthcare workers...
September 2017: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
https://www.readbyqxmd.com/read/29017278/favipiravir-and-ribavirin-treatment-of-epidemiologically-linked-cases-of-lassa-fever
#15
Vanessa N Raabe, Gerrit Kann, Bruce S Ribner, Andres Morales, Jay B Varkey, Aneesh K Mehta, G Marshall Lyon, Sharon Vanairsdale, Kelly Faber, Stephan Becker, Markus Eickmann, Thomas Strecker, Shelley Brown, Ketan Patel, Philipp De Leuw, Gundolf Schuettfort, Christoph Stephan, Holger Rabenau, John D Klena, Pierre E Rollin, Anita McElroy, Ute Ströher, Stuart Nichol, Colleen S Kraft, Timo Wolf
Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged detectable virus RNA in blood and semen, suggesting that the possibility of sexual transmission of Lassa virus should be considered.
September 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28986849/determining-the-virus-life-cycle-stage-blocked-by-an-antiviral
#16
Claudia S Sepúlveda, Cybele C García, Elsa B Damonte
Among the members of the Arenaviridae family, Junín virus and Lassa virus represent important human health threats generating annual outbreaks of severe human hemorrhagic fever (HF) in endemic areas of Argentina and Western Africa, respectively. Given the lack of a specific and safe chemotherapy, the search for effective antiviral compounds is a continuous demanding effort. During the last two decades, academic research studies originated important results identifying novel molecules to be considered for further in vivo characterization...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28986843/a-primate-model-for-viral-hemorrhagic-fever
#17
Maria S Salvato, Igor S Lukashevich, Yida Yang, Sandra Medina-Moreno, Mahmoud Djavani, Joseph Bryant, Juan David Rodas, Juan Carlos Zapata
Lymphocytic choriomeningitis virus strain WE (LCMV-WE), a Risk Group 3 virus, causes a disease in rhesus monkeys that closely resembles human infection with Lassa fever virus, a Risk Group 4 agent. Three stages of disease progression have been defined and profiled in this model: pre-viremic, viremic, and terminal. The earliest or pre-viremic stage reveals changes in the blood profile predictive of the later stages of disease. In order to identify whether specific changes are pathognomonic, it was necessary to perform a parallel infection with an attenuated virus (LCMV-Armstrong)...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28986841/murine-models-for-viral-hemorrhagic-fever
#18
Rosana Gonzalez-Quintial, Roberto Baccala
Hemorrhagic fever (HF) viruses, such as Lassa, Ebola, and dengue viruses, represent major human health risks due to their highly contagious nature, the severity of the clinical manifestations induced, the lack of vaccines, and the very limited therapeutic options currently available. Appropriate animal models are obviously critical to study disease pathogenesis and develop efficient therapies. We recently reported that the clone 13 (Cl13) variant of the lymphocytic choriomeningitis virus (LCMV-Cl13), a prototype arenavirus closely related to Lassa virus, causes in some mouse strains endothelial damage, vascular leakage, platelet loss, and death, mimicking pathological aspects typically observed in Lassa and other HF syndromes...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28986836/hemorrhagic-fever-virus-budding-studies
#19
Ronald N Harty
Independent expression of the VP40 or Z matrix proteins of filoviruses (marburgviruses and ebolaviruses) and arenaviruses (Lassa fever and Junín), respectively, gives rise to the production and release of virus-like particles (VLPs) that are morphologically identical to infectious virions. We can detect and quantify VLP production and egress in mammalian cells by transient transfection, SDS-PAGE, Western blotting, and live cell imaging techniques such as total internal reflection fluorescence (TIRF) microscopy...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28986833/expression-and-x-ray-structural-determination-of-the-nucleoprotein-of-lassa-fever-virus
#20
Xiaoxuan Qi, Wenjian Wang, Haohao Dong, Yuying Liang, Changjiang Dong, Hinh Ly
We describe methods to express the nucleoprotein (NP) of Lassa fever virus (LASV) in E. coli, to purify and crystallize it using the sitting-drop vapor diffusion method. The crystals were screened using Rigaku micro-007 X-ray generator and a dataset was collected at a resolution of 2.36 Å. The crystals belong to space group P3, with the unit cell parameters a = b = 176.35 Å, c = 56.40 Å, α = β = 90°, and γ = 120°. Using the X-ray diffraction method, we constructed a three-dimensional structure of the LASV NP that should aid in the development of novel therapeutic strategies against this virus, for which vaccine and effective treatment modalities are currently unavailable...
2018: Methods in Molecular Biology
keyword
keyword
36006
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"